Include All CSL Behring Country Sites
About CSL Behring
Quality & Safety
CSL Research & Development
European Commission Grants Marketing Authorisation to CSL Behring’s Privigen
in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
CSL Behring announced today that the European Commission has granted marketing authorisation for the use of Privigen
(human normal immunoglobulin, IVIg) 10 percent liquid in the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
CSL Behring Donates Medicine Used in Treating Bleeding Disorders to World Federation of Hemophilia
As part of its ongoing commitment to the global coagulation disorders community, CSL Behring will again donate factor product to the World Federation of Hemophilia (WFH) in connection with World Haemophilia Day this month.
CSL Behring Corporate
CSL Plasma USA
CSL Plasma Services Germany
© 2014 CSL Behring